Minimally Cytotoxic Doses of Temozolomide Produce Radiosensitization in Human Glioblastoma Cells Regardless of MGMT Expression
- 1 May 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 9 (5), 1208-1218
- https://doi.org/10.1158/1535-7163.mct-10-0010
Abstract
Concurrent treatment with the methylating agent temozolomide during radiotherapy has yielded the first significant improvement in the survival of adult glioblastomas (GBM) in the last three decades. However, improved survival is observed in a minority of patients, most frequently those whose tumors display CpG methylation of the O6-methylguanine (O6-meG)-DNA methyltransferase (MGMT) promoter, and adult GBMs remain invariably fatal. Some, although not all, preclinical studies have shown that temozolomide can increase radiosensitivity in GBM cells that lack MGMT, the sole activity in human cells that removes O6-meG from DNA. Here, we systematically examined the temozolomide dose dependence of radiation killing in established GBM cell lines that differ in ability to remove O6-meG or tolerate its lethality. Our results show that minimally cytotoxic doses of temozolomide can produce dose-dependent radiosensitization in MGMT-deficient cells, MGMT-proficient cells, and MGMT-deficient cells that lack mismatch repair, a process that renders cells tolerant of the lethality of O6-meG. In cells that either possess or lack MGMT activity, radiosensitization requires exposure to temozolomide before but not after radiation and is accompanied by formation of double-strand breaks within 45 minutes of radiation. Moreover, suppressing alkyladenine-DNA glycosylase, the only activity in human cells that excises 3-methyladenine from DNA, reduces the temozolomide dose dependence of radiosensitization, indicating that radiosensitization is mediated by 3-methyladenine as well as by O6-meG. These results provide novel information on which to base further mechanistic study of radiosensitization by temozolomide in human GBM cells and to develop strategies to improve the outcome of concurrent temozolomide radiotherapy. Mol Cancer Ther; 9(5); 1208–18. ©2010 AACR.Keywords
This publication has 45 references indexed in Scilit:
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide ResistanceClinical Cancer Research, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- DNA damage tolerance: when it's OK to make mistakesNature Chemical Biology, 2009
- γH2AX and cancerNature Reviews Cancer, 2008
- Roles of the Werner syndrome RecQ helicase in DNA replicationDNA Repair, 2008
- Eukaryotic Y-family polymerases bypass a 3-methyl-2′-deoxyadenosine analog in vitro and methyl methanesulfonate-induced DNA damage in vivoNucleic Acids Research, 2008
- Interplay of replication checkpoints and repair proteins at stalled replication forksDNA Repair, 2007
- Methylating Agents and DNA Repair Responses: Methylated Bases and Sources of Strand BreaksChemical Research in Toxicology, 2006
- Mismatch Repair-dependent Iterative Excision at Irreparable O6-Methylguanine Lesions in Human Nuclear ExtractsOnline Journal of Public Health Informatics, 2006
- Temozolomide in the treatment of solid tumours: current results and rationale for dosing/schedulingCritical Reviews in Oncology/Hematology, 2005